Clik here to view.
Nutraceutical Clinical Trial Design: Why Studies Miss Their Endpoints
Your study ran. The product may well have worked. However, the primary endpoint was not met. The sample may have been too small. Or the measurement was inconsistent across sites. Or the effect size...
View ArticleClik here to view.
Autoimmune Clinical Trials APAC: Protocol Assumptions That Slow Your Study
Your Phase II rheumatoid arthritis study is built on a protocol that worked in Europe. The comparator arm reflects European standard of care. The baseline disease activity thresholds come from US...
View ArticleClik here to view.
Full Service CRO APAC: A Sponsor’s Guide to Phase II to IV Clinical Trial...
You are planning a Phase II oncology study across three APAC markets. The protocol is close to final. Now comes the part most sponsors underestimate: selecting a CRO model that gives you execution...
View ArticleClik here to view.
Vietnam for Clinical Trials in 2026: Regulatory Landscape, Site Quality, and...
Vietnam has been on the periphery of APAC clinical trial planning for most of the last decade, considered after Thailand, Malaysia, and India if considered at all. That positioning is no longer...
View ArticleClik here to view.
Functional Service Provider (FSP) in Clinical Trials: What the Model Is, When...
The Functional Service Provider (FSP) model gives sponsors something that full-service CROs and pure in-house execution don’t: operational depth in specific markets or functions, without surrendering...
View ArticleClik here to view.
Clinical Trial Start-Up Guide in Asia-Pacific: Regulatory Timelines, Ethics...
Key takeaways Singapore and Malaysia lead APAC clinical trial start-up timelines with faster regulatory approvals, while Vietnam and Indonesia offer larger patient recruitment opportunities with...
View ArticleClik here to view.
Optimizing Clinical Trials in Triple-Negative Breast Cancer: Biomarker...
Key Takeaways from the Article Early investigator engagement improves protocol feasibility, reduces amendments, accelerates study startup timelines, and strengthens recruitment performance in TNBC...
View ArticleClik here to view.
Which Blockbuster Drugs Are Losing Patent Protection in 2028?: A Complete...
As four major blockbuster drugs losing patent protection in 2028, the pharmaceutical industry faces one of the most commercially significant exclusivity cliffs in recent years, with more than $56...
View ArticleClik here to view.
Sanfilippo Syndrome (MPS III): Disease Burden, Treatment Landscape & Research...
Key Takeaways Sanfilippo Syndrome (MPS III) is a rare, autosomal recessive lysosomal storage disorder caused by deficiencies in enzymes responsible for heparan sulfate degradation. Four biochemically...
View ArticleClik here to view.
Epidermolysis Bullosa: A Rare Disease At A Turning Point
Key Takeaways Recent approvals and pipeline focus: Two EB gene therapies, Vyjuvek (2023) and Zevaskyn (2025), were approved within 12 months, both targeting RDEB. Most late-stage programs continue to...
View ArticleClik here to view.
Amyotrophic Lateral Sclerosis (ALS): Current Treatment Landscape & Emerging...
Key Takeaways from this article — Amyotrophic Lateral Sclerosis (ALS) affects approximately 30,000 Americans at any given time, with about 5,000 new diagnoses each year in the US alone. — The global...
View ArticleClik here to view.
How to Supply Laboratory Kits to Clinical Trial Sites in Japan: A...
Japan has one of the most tightly regulated pharmaceutical landscapes, which necessitates a seamless supply of laboratory kits (for clinical trials) to its sites. The process requires strict adherence...
View ArticleClik here to view.
Transforming Clinical Trials With AI: Smarter, Faster, & More Efficient Research
Applying AI in clinical trials is no longer a futuristic concept; it’s a practical solution gaining traction across the industry. As clinical trials become increasingly complex—with growing data...
View ArticleClik here to view.
Japan Clinical Trials: Choosing the Right Sites
Japan is quickly becoming one of the most important countries in Asia for clinical research, not just because of its strong healthcare system and regulatory structure, but also due to its growing...
View ArticleClik here to view.
Key Considerations For Clinical Trials In Rare Diseases
Running a clinical trial for rare diseases is very different from trials in more common conditions. Small patient numbers, limited data, and complicated rules make every part of the process more...
View ArticleClik here to view.
First-in-Human (FIH) Clinical Trials: Key Considerations for Sponsors
Stepping into a first-in-human (FIH) clinical trial is a defining moment in drug development. It’s when a new drug that’s been years in the making finally transitions from lab bench to bedside. This...
View ArticleClik here to view.
How Engagement Impacts Patient Retention In Clinical Trials?
In clinical trials, patient engagement has a direct impact on retention, which affects how well medical research turns out overall. Keeping patients in the study is key to making sure the trial...
View ArticleClik here to view.
Regulatory Feasibility Assessment In Clinical Trials: Need And Impact
The evaluation of regulatory feasibility in clinical trials is a critical process that examines the compatibility of a trial’s design and execution with the current regulatory requirements to ensure...
View ArticleClik here to view.
A Comprehensive Overview Of Bioavailability (BA) & Bioequivalence (BE)...
Bioavailability (BA) and bioequivalence (BE) studies in India are crucial in drug development and regulatory approval processes. These studies ensure that generic drugs are therapeutically equivalent...
View ArticleClik here to view.
Effective Regulatory Life Cycle Management in Pharma: Addressing Common...
Effective regulatory management is essential for the smooth advancement of the pharmaceutical product life cycle. It focuses on several specific regulations that govern different aspects of the...
View Article
